Chiesi Farmaceutici Licenses Tum Bio’s NCE401 for $74M

 Chiesi Farmaceutici Licenses Tum Bio’s NCE401 for $74M

Chiesi Farmaceutici Licenses Tum Bio’s NCE401 for $74M

Shots:
  • Tum Bio to receive $1M upfront, up to $73M milestones and royalties on sales. Chiesi to get worldwide development and commercialization rights & will be responsible for its clinical trials
  • The focus of the agreement is to develop and commercialize NCE401, a TGF-beta inhibitor in the fields of respiratory diseases
  •  NCE401 is a preclinical candidate used for inhibiting transforming growth factor beta (TGF-β) pathway, indicated for fibrotic diseases including pulmonary fibrosis
Click here to read full press release/ article | Ref: Business Korea | Image: The Investors

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post